[go: up one dir, main page]

ATE378070T1 - Zusammensetzung mit fulvestrant - Google Patents

Zusammensetzung mit fulvestrant

Info

Publication number
ATE378070T1
ATE378070T1 AT02745579T AT02745579T ATE378070T1 AT E378070 T1 ATE378070 T1 AT E378070T1 AT 02745579 T AT02745579 T AT 02745579T AT 02745579 T AT02745579 T AT 02745579T AT E378070 T1 ATE378070 T1 AT E378070T1
Authority
AT
Austria
Prior art keywords
fulvestrant
composition
oestra
17beta
triene
Prior art date
Application number
AT02745579T
Other languages
English (en)
Inventor
Paul Gellert
Alison Potts
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE378070T1 publication Critical patent/ATE378070T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT02745579T 2001-07-07 2002-07-03 Zusammensetzung mit fulvestrant ATE378070T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116620.6A GB0116620D0 (en) 2001-07-07 2001-07-07 Formulation

Publications (1)

Publication Number Publication Date
ATE378070T1 true ATE378070T1 (de) 2007-11-15

Family

ID=9918096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745579T ATE378070T1 (de) 2001-07-07 2002-07-03 Zusammensetzung mit fulvestrant

Country Status (12)

Country Link
US (1) US20040175402A1 (de)
EP (1) EP1409021B1 (de)
JP (1) JP4295087B2 (de)
AT (1) ATE378070T1 (de)
AU (1) AU2002317298A1 (de)
CY (1) CY1107142T1 (de)
DE (1) DE60223542T2 (de)
DK (1) DK1409021T3 (de)
ES (1) ES2294146T3 (de)
GB (1) GB0116620D0 (de)
PT (1) PT1409021E (de)
WO (1) WO2003006063A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004112837A1 (ja) * 2003-05-23 2006-07-20 久光製薬株式会社 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン−１α生成抑制剤
JP5133064B2 (ja) * 2005-01-05 2013-01-30 國防教育研究基金会 ウリジン２リン酸（ｕｄｐ）−グルクロン酸転移酵素２ｂ（ｕｇｔ２ｂ）の抑制剤及び促進剤
EP1928469A4 (de) * 2005-09-26 2008-12-31 Hospira Australia Pty Ltd Fulvestrant-formulierung
MX2007006653A (es) * 2005-10-05 2009-02-17 Sicor Inc Separacion de isomeros de fulvestrant.
CA2716576A1 (en) 2008-03-07 2009-09-11 Nageswara R. Palepu Fulvestrant formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2015157752A1 (en) * 2014-04-11 2015-10-15 Sam Houston State University Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
WO2019151353A1 (ja) 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
JP4295087B2 (ja) 2009-07-15
JP2004521151A (ja) 2004-07-15
AU2002317298A1 (en) 2003-01-29
EP1409021A2 (de) 2004-04-21
DE60223542T2 (de) 2008-11-13
PT1409021E (pt) 2008-01-11
DE60223542D1 (de) 2007-12-27
WO2003006063A2 (en) 2003-01-23
ES2294146T3 (es) 2008-04-01
EP1409021B1 (de) 2007-11-14
DK1409021T3 (da) 2008-02-11
US20040175402A1 (en) 2004-09-09
GB0116620D0 (en) 2001-08-29
CY1107142T1 (el) 2012-10-24
WO2003006063A3 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
BG106833A (en) Fulvestrant formulation
BR9909329A (pt) Método para estabilizar composições farmacêuticas pelo uso especial de um antioxidante
HK1065714A1 (en) Compositions for delivery of drug combinations
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
TR200002299T2 (tr) Epotilon kompozisyonları.
NZ527157A (en) Compositions for delivering bisphosphonates
IL187813A0 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MY145074A (en) Thiazolidin-4-one derivatives
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
WO2002015959A3 (en) Compounds and compositions for delivering active agents
NO20064808L (no) Orale matrixformuleringer med licarbazepin
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
WO2004004639A3 (en) A novel stable formulation
MXPA05010613A (es) Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo.
DE60133198D1 (en) Glykopeptidderivate mit carboxysacchariden
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2369801A (en) Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation
BR0010499A (pt) Agentes endoparasiticidas
SE9902742D0 (sv) New pharmaceutical formultion
WO2004078677A3 (en) Enhanced delivery of sphingolipids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1409021

Country of ref document: EP